Hans van der Vliet
Company: Lava Therapeutics
Job title: CSO/CMO
Hans van der Vliet, MD PhD is a medical oncologist and associate professor at the department of medical oncology of the Amsterdam UMC, VU University and Cancer Center Amsterdam and scientific founder and CSO of Lava Therapeutics B.V., a biotech company that develops bispecific Vγ9Vδ2 T-cell engagers for cancer immunotherapy. He received his MD from the University of Amsterdam and his PhD (cum laude) and internal medicine/medical oncology specialization from the VU University in Amsterdam.
Bispecific γδ-T cell Engagers for Cancer Immunotherapy 2:30 pm
Background on Vγ9Vδ2 T cells and their role in antitumor immunity Generation and preclinical evaluation of bispecific Vγ9Vδ2 T cell engagers as novel tools for cancer immunotherapyRead more
day: Day Two